ALK and non-small cell lung carcinoma: The antitumor efficacy of crizotinib has been demonstrated in multiple clinical trials, showing significant therapeutic benefits, particularly in ALK-positive NSCLC (Shaw et al., 2020; Shaw et al., 2019).